Lyell Immunopharma Reports $38.8 Million Net Loss in Q3 2025, Revenue Declines

Lyell Immunopharma, Inc. reported a net loss of $38.8 million for the third quarter of 2025, a decrease from a net loss of $44.6 million in the same period last year. Revenue for the quarter was $15,000, down from $34,000 in the prior year. For the nine months ending September 30, 2025, the company recorded a net loss of $133.7 million, compared to a loss of $151.1 million for the same period in 2024. The decrease in losses is attributed to reduced operating expenses, which totaled $37.3 million for the quarter, down from $50.5 million in the previous year, and $141.8 million for the nine months, down from $157.7 million.

The company has made significant strides in its operational strategy, including the successful transition of manufacturing for its lead product candidate, rondecabtagene autoleucel (ronde-cel), to its LyFE Manufacturing Center in Bothell, Washington. This transition is expected to enhance production efficiency and support ongoing clinical trials. Additionally, Lyell Immunopharma has expanded its pipeline by acquiring exclusive global rights to LYL273, a novel CAR T-cell product candidate targeting guanylyl cyclase-C for the treatment of metastatic colorectal cancer and other GCC-expressing cancers.

As of September 30, 2025, Lyell Immunopharma had total assets of $408 million, a decrease from $491 million at the end of 2024. The company’s cash and cash equivalents increased to $123.6 million from $105.6 million, while marketable securities decreased to $196 million from $265 million. The company’s total liabilities also decreased significantly to $78.8 million from $108 million, primarily due to a reduction in accrued liabilities and contingent consideration payable.

Looking ahead, Lyell Immunopharma anticipates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months. The company plans to continue its focus on advancing its clinical trials, particularly the pivotal trials for ronde-cel and LYL273, while also exploring additional funding opportunities to support its research and development efforts. The company has expressed confidence in its strategic direction and the potential of its product candidates to address significant unmet medical needs in oncology.